Form 4: Cabaletta Bio Officer Gwendolyn Binder Reports Stock Option Grant
SEC Form 4 Filing
Gwendolyn Binder, President of Science & Technology at Cabaletta Bio, Inc., reports the acquisition of stock options.
Summary
- Gwendolyn Binder, President of Science & Technology at Cabaletta Bio, Inc., filed a Form 4 on March 4, 2025, reporting a transaction.
- On March 3, 2025, Binder acquired stock options for 145,000 shares of Cabaletta Bio common stock at an exercise price of $1.67.
- These options vest over time, with 25% vesting on March 3, 2026, and the remainder vesting in equal quarterly installments thereafter, contingent upon continued service.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating confidence in the company's future.
Positives
- The granting of stock options to a key officer like the President of Science & Technology can be seen as an incentive to align their interests with the long-term success of the company.
Future Outlook
The vesting schedule of the options suggests a commitment from the reporting person to remain with the company for at least three years.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize key employees and align their interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in biotech companies, often benchmarked against peer companies of similar size and stage of development.
- Vesting schedules, like the one described, are typical, designed to retain talent and incentivize long-term performance.
- The specific number of options granted and the exercise price would be determined based on factors such as the executive's role, performance, and the company's overall compensation strategy.
Stakeholder Impact
- The stock option grant could potentially incentivize the officer to make decisions that benefit shareholders in the long term.
- Employees may view the grant as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date of stock option grant. |
| 03/03/2026 | First vesting date for 25% of the stock options. |
| 03/02/2035 | Expiration date of the stock options. |
| 03/04/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.